ACC 2023 | A DUE-Study (Phase III)

In pulmonary hypertension (PHT), 10 mg macitentan plus 40 mg tadalafil is recommended as a safe combination therapy for newly diagnosed patients or in a significant proportion of patients during follow-up. Using a tablet with a fixed drug combination (FDC) could simplify treatment.

ACC 2023 | A DUE-Study (Fase III)

The aim of this study was to evaluate the efficacy and safety of macitentan/tadalafil in FDC vs. macitentan and tadalafil monotherapy in patients with PHT. It was a randomized, prospective, multicenter, double-blind, phase III study, with a 16-week follow-up.

The study included patients who were treatment-free or who had stable doses of endothelin receptor antagonists or stable doses of phosphodiesterase-5 inhibitors, with a subsequent 1:2 randomization to macitentan 10 mg, macitentan/tadalafil, or tadalafil 40 mg. 

Efficacy outcomes were studied at 16 weeks. The primary endpoint was change in pulmonary vascular resistance (PVR) from baseline. The secondary endpoint was change in the 6-minute walk test (6MWT). The safety and tolerability of the treatment were also evaluated.

Read also: ACC 2023 | Ultrasensitive Troponin I Monitoring with a Transdermal Wrist Device.

The study enrolled 187 randomized patients. The combination in FDC decreased PVR by 45% from baseline, in contrast to macitentan, which decreased it by 23% (mean ratio: 0.71: 95% confidence interval [CI]: 0.71-0.82; p ≤ 0.0001). When compared with tadalafil, the difference in pulmonary resistance was 28% better (average ratio: 0.72, 95% CI: 0.64-0.80; p ≤ 0.0001). However, there was a nonsignificant difference from baseline when analyzing the 6MWT (p = 0.380).

Conclusions: The combination of macitentan and tadalafil at fixed doses significantly decreased (28%) pulmonary vascular resistance.

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Original Title: “Efficacy And Safety Of Macitentan Tadalafil Fixed Dose Combination In Pulmonary Arterial Hypertension: Results From The Randomized Controlled Phase III A DUE Study”.

Reference: Presentado por Kelly Chin en Late Breaking Trials del ACC.23/WCC Marzo 4-6, 2023, en New Orleans.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

TAVR and Anticoagulation: What Should We Do?

Transcatheter aortic valve replacement (TAVR) has consolidated as a valid strategy for certain groups of patients. However, approximately one third of those who require...

Direct Oral Anticoagulants for Ventricular Thrombus After STEMI

While the incidence of intracavitary thrombi after acute myocardial infarction (AMI) has decreased thanks to optimized primary angioplasty times, some studies report rates of...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...